- Home
- BTMD vs IPHA Comparison
BTMD vs IPHA Comparison
Compare BTMD & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTMD
- IPHA
- Stock Information
- Founded
- BTMD 2012
- IPHA 1999
- Country
- BTMD United States
- IPHA France
- Employees
- BTMD N/A
- IPHA N/A
- Industry
- BTMD Medicinal Chemicals and Botanical Products
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- BTMD Health Care
- IPHA Health Care
- Exchange
- BTMD Nasdaq
- IPHA Nasdaq
- Market Cap
- BTMD 136.0M
- IPHA 160.1M
- IPO Year
- BTMD N/A
- IPHA 2019
- Fundamental
- Price
- BTMD $3.31
- IPHA $1.97
- Analyst Decision
- BTMD Strong Buy
- IPHA Strong Buy
- Analyst Count
- BTMD 1
- IPHA 1
- Target Price
- BTMD $8.00
- IPHA $11.50
- AVG Volume (30 Days)
- BTMD 174.5K
- IPHA 28.4K
- Earning Date
- BTMD 05-06-2025
- IPHA 03-27-2025
- Dividend Yield
- BTMD N/A
- IPHA N/A
- EPS Growth
- BTMD N/A
- IPHA N/A
- EPS
- BTMD 0.09
- IPHA N/A
- Revenue
- BTMD $197,191,000.00
- IPHA $20,831,349.00
- Revenue This Year
- BTMD $6.20
- IPHA $220.44
- Revenue Next Year
- BTMD $9.24
- IPHA $81.85
- P/E Ratio
- BTMD $38.33
- IPHA N/A
- Revenue Growth
- BTMD 6.38
- IPHA N/A
- 52 Week Low
- BTMD $3.04
- IPHA $1.29
- 52 Week High
- BTMD $8.44
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- BTMD 40.79
- IPHA 53.30
- Support Level
- BTMD $3.09
- IPHA $1.81
- Resistance Level
- BTMD $3.79
- IPHA $2.00
- Average True Range (ATR)
- BTMD 0.26
- IPHA 0.14
- MACD
- BTMD 0.03
- IPHA 0.02
- Stochastic Oscillator
- BTMD 31.72
- IPHA 53.76
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.